63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021)

Non-O blood type appears to be a risk factor for cancer-associated venous thromboembolism (VTE), particularly in patients who have cancer types with low to intermediate thrombotic risk, according to data from the Cancer and Thrombosis Study (CATS) presented at ASH 2021.

Long-term treatment with givosiran showed continued reduction in the composite annualized attack rate (AAR) of porphyria among patients with acute hepatic porphyria (AHP), according to the ENVISION* open-label extension (OLE) study presented at ASH 2021.

One-time gene therapy in patients with transfusion-dependent β-thalassemia (TDT) results in near-normal or normal haemoglobin levels and transfusion independence, suggesting its curative potential, a long follow-up study has shown.

The combination of ivosidenib and azacitidine (IVO-AZA) improves event-free and overall survival (OS) vs AZA alone in patients with acute myeloid leukaemia (AML) bearing somatic mutations in isocitrate dehydrogenase 1 (IDH1), the AGILE trial has shown.

Prophylactic use of the investigational antithrombin siRNA fitusiran significantly reduces bleeding events in people with severe haemophilia compared with on-demand treatment with clotting factor concentrates, according to the phase III ATLAS-A/B trial presented at ASH 2021.

Low vitamin D levels were associated with an increased incidence of pain events leading to hospital admission among children with sickle cell disease (SCD), according to a study presented at ASH 2021.